The FDA approved expanded indications of Yuflyma and its unbranded version to treat hidradenitis suppurativa in adolescents aged 12 years and older and uveitis in children aged 2 years and older, according to a press release.Yuflyma (adalimumab-aaty, C…
FDA approves Epioxa for keratoconus
The FDA approved Epioxa for the treatment of keratoconus, Glaukos announced in a press release.“We’re proud to announce an extraordinary milestone for keratoconus patients with the approval of Epioxa,” Thomas Burns, Glaukos chairman and CEO, told Heali…
Science Corp.’s PRIMA BCI Implant Restores Functional Central Vision to Patients with Geographic Atrophy Caused By Age-Related Macular Degeneration, a Leading Cause of Blindness, The New England Journal of Medicine Reports
ALAMEDA, Calif.–(BUSINESS WIRE)–The New England Journal of Medicine (NEJM) today published a peer-reviewed original paper with the results of a landmark clinical trial demonstrating the efficacy of Science Corporation’s PRIMA brain-computer interface…
Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potentially best-in-class medicines for serious and rare diseases, today announced it entered in…
Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)
BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicines, today announced the presentation of two-year data from th…
STAAR Surgical Announces Preliminary Net Sales Results for Third Quarter 2025
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced preliminary net sales results for the th…